TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations

Abstract excerpt

BACKGROUND: The activity of PARP inhibitors (PARPi) in patients with homologous recombination repair (HRR) mutations and metastatic castration-resistant prostate cancer has been established. We hypothesized that the benefit of PARPi can be maintained in the absence of androgen deprivation therapy (ADT) in an HRR-mutated population. We report the results of a phase II clinical trial of rucaparib monotherapy in...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to PARP inhibition in cancer therapy
• Share to Prostate Cancer Diagnosis and Treatment
• Share to Prostate Cancer Treatment and Research